Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to Presi...
April 05 2018 - 4:05PM
Trevena, Inc. (NASDAQ:TRVN) today announced that President and
Chief Executive Officer Maxine Gowen, Ph.D., will retire on October
1, 2018. The Board of Directors has selected Carrie L.
Bourdow, who currently serves as Trevena’s Executive Vice President
and Chief Operating Officer, to be the Company’s next President and
Chief Executive Officer, effective October 1, 2018. Dr. Gowen will
continue to serve on the Trevena Board of Directors.
Ms. Bourdow has served in various senior positions at Trevena
since May 2015. She joined the Company as Chief Commercial Officer,
and was appointed Executive Vice President and Chief Operating
Officer in January 2018.
“Max has led Trevena from its inception, through numerous
evolutions, and to the cusp of potential approval of its first
product,” said Lonnie Moulder, Chair of the Trevena Board of
Directors. “Under her leadership, the Company has advanced
several innovative molecules into clinical development and had its
first New Drug Application accepted for review by the U.S. Food and
Drug Administration. In addition, she has built a terrific
team that has positioned the Company for strong growth in the
future. On behalf of the Board and everyone at Trevena, I
thank Max for her exceptional leadership during her time at Trevena
and her continued contributions through this transition period and
as a director.”
Mr. Moulder continued, “At the same time, we are thrilled to
have Carrie become Trevena’s next CEO. She has already
assumed increasing leadership responsibilities since joining
Trevena, and brings the experiences and leadership skills we
believe the Company needs to thrive in the future.
“I am honored by this opportunity and the confidence the Board
has placed in me,” said Ms. Bourdow. “I joined Trevena three years
ago because I saw the potential for us to provide meaningful
products to patients and practitioners. I am confident that
the Company is positioned for success and look forward to leading
our tremendous team as we focus on delivering value for patients,
providers, and stockholders.”
“It’s been a privilege to lead the team at Trevena, and an honor
to work with some of the brightest and most dedicated individuals
I’ve met in our industry,” said Dr. Gowen. “I’m extraordinarily
proud of what we’ve built at Trevena, and confident in Carrie’s
leadership as she and the rest of the Trevena team forge a path to
grow the business in the coming years.”
Prior to joining Trevena, Ms. Bourdow was vice president of
marketing at Cubist Pharmaceuticals, Inc., until its acquisition by
Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow
led launch strategy, marketing, reimbursement, and operations for
five acute care hospital pharmaceuticals totaling over $1 billion
in annual revenues. Before joining Cubist in 2013, Ms. Bourdow
served for more than 20 years at Merck & Co., Inc., where she
held positions of increasing responsibility across several
therapeutic areas including anti-infectives, acute heart failure,
and pain. Since June 2017, she has served on the board of Nabriva
Therapeutics plc., a publicly traded biopharmaceutical company.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on
providing better, safer therapies to patients in pain. The
Company has leveraged breakthrough science to discover and develop
its investigational product oliceridine injection for the
management of moderate-to-severe acute pain. Oliceridine has
been granted Breakthrough Therapy designation by the U.S. Food and
Drug Administration, and is intended to provide healthcare
providers an innovative new option for patients who require an
intravenous opioid. The Company also has an early stage pipeline of
new chemical entities targeting novel mechanisms of action,
including TRV250 for acute migraine, neuropathic pain, and other
indications.
Cautionary note on forward looking
statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development of its
therapeutic candidates, plans for potential future product
candidates and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “suggest,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
status, timing, costs, results and interpretation of the Company’s
clinical trials; the uncertainties inherent in conducting clinical
trials; expectations for regulatory approvals, including whether
the oliceridine NDA will be approved by FDA; availability of
funding sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements;
uncertainties related to the Company’s intellectual property; other
matters that could affect the availability or commercial potential
of the Company’s therapeutic candidates; and other factors
discussed in the Risk Factors set forth in the Company’s Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q filed with
the Securities and Exchange Commission (SEC) and in other filings
the Company makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
the Company’s views only as of the date hereof. The Company
anticipates that subsequent events and developments may cause the
Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so, except
as may be required by law.
Contacts
Trevena, Inc.
Investors:Jonathan Violin, Ph.D.Senior Vice
President, Scientific Affairs & Investor Relations
Officer610-354-8840 x231jviolin@trevena.com
or
Media:Public RelationsPR@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Sep 2023 to Sep 2024